
AI‑QUAL: The New AI Tool That Makes Prostate MRI Scans More Accurate
AI tools are now being used in many hospitals to help doctors catch issues faster, avoid repeat scans, and follow global quality standards. Whether it's a chest CT or a prostate MRI, AI makes the scanning process smoother and more accurate. One such tool is AI‑QUAL by Quibim, a Spanish health-tech company. It checks prostate MRI images and tells the radiologist if the scan meets global quality rules. This means better care for patients, less waiting, and more confidence in the results.
What is AI‑QUAL?
AI‑QUAL is a smart tool that helps doctors check the quality of prostate MRI scans. It works like an assistant that looks at the images and makes sure they are clear and correct. If something is missing or blurry, it gives a quick warning so the team can fix it right away.
This tool was made by Quibim, a health-tech company based in Spain. They added AI‑QUAL to their special platform called QP‑Prostate, which is already used for prostate imaging. The goal is to help doctors get the best possible images, without wasting time or asking patients to come back for another scan.
AI‑QUAL follows a global quality rule called PI‑QUAL version 2. This rule tells doctors what a good prostate MRI should look like. By using AI‑QUAL, hospitals and clinics can follow these standards easily and give patients faster, more reliable results.
How AI‑QUAL Works
AI‑QUAL works quietly in the background during prostate MRI scans. As the images are taken, the tool checks them one by one. It looks for small problems—like missing angles, unclear spots, or wrong settings. If something isn't right, it sends an alert to the radiology team right away.
The smart part? It uses a system called PI‑QUAL v2, which is a global guideline for prostate MRI quality. This means AI‑QUAL knows exactly what a good scan should include. Doctors don't have to guess—they get quick, automatic feedback during the scan itself. That saves time and helps avoid repeat scans later.
AI‑QUAL is fully built into Quibim's QP‑Prostate platform, so it fits smoothly into the daily work of hospitals and clinics. Instead of slowing things down, it makes the process faster and more reliable. In short, it acts like an extra pair of expert eyes—always on, always checking, always ready to help.
Key Benefits for Users
1. Doctors and Radiology Teams
Fast, automatic checks. AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away.
AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away. Fewer blind spots. The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors.
The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors. Clear next steps. A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait.
A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait. More confidence. Radiologists start reading with sharper scans, which helps them trust their findings and report faster.
Quick check: When was the last time your team lost minutes debating scan quality? AI-QUAL makes that question disappear.
2. Patients and Families
One visit, one scan. Good images the first time mean fewer callbacks and less travel.
Good images the first time mean fewer callbacks and less travel. Earlier answers. Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment.
Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment. Lower stress. No extra appointments, no extra prep—just a smoother experience from start to finish.
3. Hospitals and Clinics
Standardized quality. AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark.
AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark. Time saved. Automated scoring removes manual checks and frees staff for patient care.
Automated scoring removes manual checks and frees staff for patient care. Better workflow. Fewer retakes keep MRI rooms moving and improve daily throughput.
Fewer retakes keep MRI rooms moving and improve daily throughput. Reputation boost. Consistent, high-quality imaging builds trust with referring doctors and patients alike.
4. Health Systems & Researchers
Reliable data. Consistent images make clinical trials cleaner and AI training sets stronger.
Consistent images make clinical trials cleaner and AI training sets stronger. Cost control. Cutting unnecessary repeat scans reduces energy use, staff time, and overall imaging costs.
Use Cases & Real-Life Examples
1. Busy Hospitals with High MRI Volume
In many large hospitals, radiology teams handle dozens of MRI scans every day. Sometimes, due to time pressure, a low-quality scan slips through. With AI‑QUAL, that changes. For example, if a technician misses an important view during a prostate scan, the tool immediately detects it and asks for a retake—before the patient leaves the room. This saves time, avoids rescheduling, and speeds up diagnosis.
2. Small Clinics with New Staff
Smaller clinics or centers with new MRI staff often face training challenges. AI‑QUAL acts like a helpful coach. It checks every scan and gives instant feedback. This means even junior technicians can follow best practices and deliver high-quality images, right from day one. It helps build confidence and maintain professional standards.
3. Research Centers and Clinical Trials
Medical researchers rely on clean, consistent images when studying new treatments or testing new technologies. If one scan in a clinical trial is blurry or incomplete, it could affect the results. That's why some research hospitals are using AI‑QUAL to make sure every scan meets the same quality level. This makes the data more trustworthy and easier to analyze.
Disadvantages and Limitations of AI‑QUAL
While AI‑QUAL is a helpful tool, it's not perfect. Like any new technology, it comes with a few challenges that clinics and hospitals should keep in mind.
1. It doesn't replace human judgment
AI‑QUAL checks image quality, not medical results. It won't spot cancer or give a diagnosis. Doctors still need to review each scan carefully. Over-relying on AI might cause people to skip important double-checks.
2. Works only with prostate MRI
Right now, AI‑QUAL is designed just for prostate MRI scans. That means it doesn't help with other types of imaging like chest CTs, brain MRIs, or full-body scans. Clinics must use different tools for other exams.
3. Needs proper setup
To use AI‑QUAL, you need Quibim's QP‑Prostate platform. This could mean new software installation, staff training, and possible updates to your current systems. Smaller clinics may find this a bit tricky or costly at first.
4. May not detect all issues
While AI‑QUAL follows global quality rules, it still depends on the data it was trained on. In rare cases, it might miss unusual problems or give false alerts. That's why human review is always important.
Expected Trends in the Future
AI‑QUAL is a strong first step, but it's just the beginning. The future of this technology looks promising, with some exciting improvements likely coming soon.
1. Expanding Beyond Prostate MRI
Right now, AI‑QUAL only works with prostate MRI scans. In the future, we may see Quibim expand this tool to cover other body parts—like brain, spine or liver MRIs. That would make the technology more useful across different departments in hospitals and imaging centers.
2. Smarter Feedback with Real-Time Guidance
Today, AI‑QUAL checks the image and tells if it's good or not. But soon, it might also guide the technician step-by-step during the scan. For example, it could say: 'Tilt slightly left' or 'Scan missed the top area'—making scans better without needing a retake.
3. Combining AI-QUAL with Diagnosis Tools
In the future, AI‑QUAL might work alongside tools that don't just check image quality but also help detect tumors or disease signs right away. Imagine one smart system that says, 'Image looks good and here's something the doctor should see.'
4. Easier Use in Small Clinics
As AI‑QUAL improves, it could become easier to install, cheaper to run, and more user-friendly for small clinics with fewer staff. This would help more communities benefit from high-quality imaging.
5. Better Reporting and Learning
Future versions may come with dashboards showing scan quality trends over time. This can help hospitals train staff better, improve equipment use, and even reduce costs by avoiding repeat scans.
Conclusion
AI‑QUAL by Quibim is a big step forward in making prostate MRI scans more reliable. It uses smart technology to check image quality in real-time, helping doctors get clearer pictures and make better decisions. For patients, this means fewer repeat scans, faster results, and more peace of mind.
While it has a few limits like working only with prostate MRI for now, its future looks bright. With time, we may see tools like AI‑QUAL used across more types of scans and in more hospitals, big and small. As medical imaging continues to grow, AI‑QUAL is leading the way toward a smarter, faster, and more accurate healthcare system.
FAQs about AI-QUAL
Here is the list of Frequently asked questions related to this amazing AI Tool:
1. How much does AI‑QUAL cost for a hospital or clinic?
The exact cost of AI‑QUAL isn't listed online. Pricing usually depends on how many scans the hospital does and how big the imaging team is. Most AI tools like this charge either a yearly fee or a price per scan. Hospitals and clinics need to contact Quibim directly to get a custom quote based on their needs.
2. Is AI‑QUAL approved by medical authorities like the FDA?
Yes. AI‑QUAL is part of Quibim's QP‑Prostate platform, which has received FDA 510(k) clearance in the U.S., CE marking in Europe, and UKCA approval in the UK. That means it's already allowed for clinical use in many countries. Still, every hospital should double-check with local health regulators before using the tool.
3. How accurate is AI‑QUAL compared to human radiologists?
AI‑QUAL doesn't diagnose cancer—it only checks if the MRI image is clear and complete. It gives a score based on international standards (called PI‑QUAL v2). So far, there's no public data showing how well it performs compared to radiologists. Doctors still need to review all images, just like before.
4. Will it work with any MRI machine?
Yes, in most cases. AI‑QUAL works with standard DICOM images, which are used by all major MRI machine brands. However, Quibim recommends doing a quick check during setup to make sure everything connects smoothly.
5. How long does it take to train staff?
Training doesn't take long. Most technologists can learn the basics in half a day, and radiologists often get comfortable with it after just one session. If your hospital uses a custom setup, you might need a little extra time for staff orientation.
6. What happens to patient data and privacy?
AI‑QUAL is designed with privacy and security in mind. It uses encrypted data and follows rules like HIPAA in the U.S. and GDPR in Europe. Patient images stay inside the hospital's system or a secure cloud. Only the quality score is shared on the screen where doctors read the scan.
7. Can AI‑QUAL be used for children?
No. AI‑QUAL is built for adult prostate MRI scans only. It's not tested or approved for children. Pediatric imaging needs different tools and guidelines.
8. How does it handle tricky cases like metal implants?
AI‑QUAL can detect issues like metal streaks, motion blur, or gas bubbles—things that can make images unclear. When it finds these problems, it asks for a quick retake of the scan. But doctors still decide if the new images are good enough.
9. Does it need an internet connection to work?
Not always. AI‑QUAL runs locally at the hospital, so it can work even without the internet. But to get software updates and support from Quibim, it's helpful to have occasional internet access.
10. How often does it need updates or support?
Like most software, AI‑QUAL gets updates for security and new features. Updates usually come every few months and can install automatically. Most hospitals also get a support contract when they buy the license, which covers help and maintenance.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Himax Technologies (HIMX) and Rabboni Co. Jointly Announce Unveiling of bboni Ai
Himax Technologies, Inc. (NASDAQ:HIMX) is one of the Best Semiconductor Stocks to Buy Under $20. On July 14, Himax Technologies, Inc. (NASDAQ:HIMX) and Rabboni Co., Ltd. jointly announced the unveiling of bboni Ai, which is the world's first multi-scenario endpoint AI sensing system. Notably, bboni Ai tends to integrate Rabboni's high-precision IMU (Inertial Measurement Unit) motion sensors with Himax Technologies, Inc. (NASDAQ:HIMX)'s ultralow-power WiseEye2 AI processor. This opens a new chapter for real-time endpoint AI inference for wearable devices and ramps up the transition of AI from concept to real-world implementation. An aerial view of a modern fabrication center with equipment for producing semiconductor components. The tariffs have not had a significant direct impact on the company's business, as its IC products are not directly exported to the US. Amidst the volatile macro environment, most of the panel customers adopted a make-to-order model and have decided to keep inventories lean. Therefore, Himax Technologies, Inc. (NASDAQ:HIMX) continues to carefully monitor wafer-starts, maintains low inventory levels, and remains focused on controlling operating expenses. Despite the near-term challenges, Himax Technologies, Inc. (NASDAQ:HIMX) leads the global automotive display market, accounting for a 40% share in DDIC, more than 50% in TDDI, and an even higher share in cutting-edge local dimming Tcon technologies. Himax Technologies, Inc. (NASDAQ:HIMX) is a fabless semiconductor company that offers display imaging processing technologies. While we acknowledge the potential of HIMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
CAS SciFinder integrates transformative new science-smart AI capabilities to enhance R&D efficiency and boost innovation
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery COLUMBUS, Ohio, Aug. 4, 2025 /CNW/ -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the launch of the next evolution of CAS SciFinder®, the leading scientific search and insights platform. By integrating advanced AI—optimized for scientific applications—with the largest human-curated collection of global scientific knowledge, CAS SciFinder empowers researchers across R&D to work faster and unlock new opportunities for innovation. This marks the most significant integration of AI within the CAS solution portfolio to date. "Scientific information is diverse and complex, making it challenging for common AI tools to interpret accurately," noted Tim Wahlberg, CAS Chief Product Officer. "Applying these technologies to the high-quality, structured data in the CAS Content Collection™ and engaging our team of scientists to verify the advanced AI models enabled us to develop a science-smart AI approach that delivers accurate and reliable answers scientists can trust." SearchSense, a collection of new AI-driven search capabilities in CAS SciFinder, was developed to make scientific information more accessible across R&D workflows and help researchers reach actionable answers faster. With a single search box, users can initiate a broad range of inquiries by asking simple questions using natural language. AI-enabled summaries help users quickly interpret results and pinpoint the most relevant information to provide a clear answer they trust. Ninety-three percent of beta testers agree that the new search features in CAS SciFinder make them more efficient. The platform also learns from user activity to personalize results and streamline future searches. To ensure the security of all user queries, results, and interactions in CAS SciFinder, AI features operate within a closed system. CAS also continues to lead innovation in retrosynthesis with the introduction of the first real-time, interactive synthetic planning tool. This is a paradigm shift for chemists that slashes the time needed to generate a synthetic plan from minutes to just a few seconds. By eliminating wait times and providing real-world evidence directly in synthetic maps for quick comparison, Interactive Retrosynthesis in CAS SciFinder significantly increases efficiency and enables greater creativity in reaction planning and optimization. Scientist-enhanced AI is also being leveraged for more accurate interpretation of users' reaction queries to deliver unmatched search accuracy and precision within the largest collection of curated reaction information. To address a growing need among scientists and stakeholders in all phases of R&D to have greater visibility of the intellectual property (IP) landscape, additional IP search support, visualization capabilities, and patent details have also been added to CAS SciFinder. Users can now easily identify prior art within their typical workflow with the help of IP Connections. This CAS-developed AI algorithm matches relevant patent and non-patent publications from any free-text input to inform more confident prioritization and reduce the risk of wasted time and investment. "The process of scientific discovery is constantly evolving, and we are committed to advancing our solutions with the latest technology to provide the best insights, most efficient workflow, and an optimal user experience to meet our customers' changing needs," said Manuel Guzman, President of CAS. "With so many scientists around the globe relying on CAS SciFinder, these new capabilities meaningfully impact the speed of discovery and ultimately help deliver life-changing innovations faster. Visit the CAS SciFinder preview site to learn more about the new features, which will be deployed to users in phases over the next two months. About CAS CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today's complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. Connect with us at CAS is a division of the American Chemical Society. Logo - View original content: SOURCE CAS View original content: Sign in to access your portfolio


Business Wire
2 hours ago
- Business Wire
Mitsubishi Electric Begins Supplying Traction Systems for Nederlandse Spoorwegen's Double-Decker New Generation Trains
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has begun supplying Spanish rolling-stock builder Construcciones y Auxiliar de Ferrocarriles, S.A. (CAF) with traction systems for 60 trains (300 cars in total) in the Double-Decker New Generation (DDNG) trains operated by the Dutch railway company Nederlandse Spoorwegen (NS). Deliveries started in July. Mitsubishi Electric expects to supply NS with traction systems for 266 trains (1,006 cars) by 2031, including equipment for 206 trains (706 cars) in NS's Sprinter New Generation (SNG) trains supplied separately through 2022 under contracts awarded by CAF in 2015 and 2019. The equipment supplied by Mitsubishi Electric for the SNG trains has been in commercial operation since 2018. The systems' track record of contributing to safe and reliable rail operations in the Dutch market played a crucial role in CAF and NS selecting Mitsubishi Electric to supply traction systems for the new DDNG trains. In a related development, MEDCOM Sp. Z o.o., a Polish manufacturer of railcar traction systems in which Mitsubishi Electric is a capital partner, was awarded a contract to supply DDNG trains with auxiliary power supply units. Mitsubishi Electric has been working closely with MEDCOM since 2015 to strengthen its customer network in Europe. Going forward, Mitsubishi Electric remains committed to contributing to safe and reliable railway operations in the European market.